37 results on '"Mizukami, Takuro"'
Search Results
2. Decision making for anti-VEGF inhibitor continuation: dip stick? or urine protein/creatinine ratio? (VERSiON UP study)
3. Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild‐type metastatic colorectal cancer: A phase II trial (HYBRID)
4. Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan
5. Clinical utility of geriatric assessment tools in older patients with gastrointestinal cancer
6. A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol
7. Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study
8. O1-6 REVIVE study: An observational study in chemotherapy (CTx) after nivolumab (NIVO) for advanced gastric cancer (AGC)
9. The Molecular Landscape of Pancreatobiliary Cancers for Novel Targeted Therapies From Real-World Genomic Profiling
10. Additional file 7 of Decision making for anti-VEGF inhibitor continuation: dip stick? or urine protein/creatinine ratio? (VERSiON UP study)
11. Additional file 6 of Decision making for anti-VEGF inhibitor continuation: dip stick? or urine protein/creatinine ratio? (VERSiON UP study)
12. Endoscopic duodenal stent placement versus gastrojejunostomy for unresectable pancreatic cancer patients with duodenal stenosis before introduction of initial chemotherapy (GASPACHO study): a multicenter retrospective study
13. Prediction of esophagogastric varices associated with oxaliplatin administration
14. Role of nutritional care and general guidance for patients with advanced or metastatic gastric cancer
15. MO1-2 Geriatric assessment and clinical outcomes for elderly colorectal cancer patients
16. An observational study on nutrition status in gastric cancer patients receiving ramucirumab plus taxane: BALAST study
17. P31-7 Clinical outcomes of cerebral infarction associated with Trousseau’s syndrome in advanced pancreatic cancer patients
18. REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer
19. Prospective evaluation and refinement of an S‐1 dosage formula based on renal function for clinical application
20. Inferior mesenteric arteriovenous fistula during treatment with bevacizumab in colorectal cancer patient: A case report
21. Endoscopic duodenal stent placement versus gastrojejunostomy for unresectable pancreatic cancer patients with duodenal stenosis before introduction of initial chemotherapy (GASPACHO study): a multicenter retrospective study.
22. Additional file 2: of A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol
23. Additional file 1: of A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol
24. Association of gastric acid suppression with efficacy of immune checkpoint inhibitors (ICIs) in advanced cancer patients
25. Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy
26. Abstract CT052: Phase I study of the anti-heparin binding-EGF antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer
27. Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib
28. MO3-10-2 - Association of gastric acid suppression with efficacy of immune checkpoint inhibitors (ICIs) in advanced cancer patients
29. Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison
30. Development of dosing recommendation of S-1 for patients with renal dysfunction by prospective pharmacokinetic study
31. EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition
32. Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study
33. Abstract 5456: FGF9 gene amplification can induce resistance to anti-EGFR therapy in colorectal cancer
34. Predictability of antitumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer following failure of fluorouracil, irinotecan and oxaliplatin
35. MEK Inhibitor for Gastric Cancer with MEK1 Gene Mutations
36. Loss of Tie2 receptor compromises embryonic stem cell-derived endothelial but not hematopoietic cell survival
37. The Molecular Landscape of Pancreatobiliary Cancers for Novel Targeted Therapies From Real-World Genomic Profiling.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.